OTCMKTS:ALPMY Astellas Pharma (ALPMY) Stock Price, News & Analysis $10.09 -0.04 (-0.39%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest About Astellas Pharma Stock (OTCMKTS:ALPMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Astellas Pharma alerts:Sign Up Key Stats Today's Range$9.73▼$10.1150-Day Range$10.07▼$12.3052-Week Range$9.15▼$13.14Volume150,540 shsAverage Volume170,771 shsMarket Capitalization$18.26 billionP/E Ratio48.05Dividend Yield2.97%Price TargetN/AConsensus RatingN/A Company OverviewAstellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Read More… Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Receive ALPMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ALPMY Stock News HeadlinesAstellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure ManagementNovember 20 at 1:00 PM | prnewswire.comAstellas Pharma (OTCMKTS:ALPMY) & ADC Therapeutics (NYSE:ADCT) Critical ReviewNovember 20 at 2:53 AM | americanbankingnews.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 23, 2024 | Priority Gold (Ad)Astellas Faces FDA Setback on IZERVAY ApplicationNovember 18, 2024 | markets.businessinsider.comABIVAX Société Anonyme (NASDAQ:ABVX) versus Astellas Pharma (OTCMKTS:ALPMY) Financial ContrastNovember 14, 2024 | americanbankingnews.comAstellas Pharma H1 Profit Rises; Lifts FY24 OutlookOctober 30, 2024 | markets.businessinsider.comAstellas Pharma Withdraws EU Application for Key DrugOctober 28, 2024 | markets.businessinsider.comBernstein Releases a Buy Rating on Astellas Pharma (ALPMF)October 23, 2024 | markets.businessinsider.comSee More Headlines ALPMY Stock Analysis - Frequently Asked Questions How have ALPMY shares performed this year? Astellas Pharma's stock was trading at $11.90 at the start of the year. Since then, ALPMY stock has decreased by 15.2% and is now trading at $10.09. View the best growth stocks for 2024 here. How were Astellas Pharma's earnings last quarter? Astellas Pharma Inc. (OTCMKTS:ALPMY) announced its earnings results on Wednesday, October, 30th. The company reported $0.13 earnings per share for the quarter. The business earned $3.11 billion during the quarter. Astellas Pharma had a trailing twelve-month return on equity of 10.33% and a net margin of 3.26%. When did Astellas Pharma's stock split? Shares of Astellas Pharma split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split. Does Astellas Pharma have any subsidiaries? The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and more. How do I buy shares of Astellas Pharma? Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings10/30/2024Today11/23/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ALPMY CUSIPN/A CIK1446390 Webwww.astellas.com Phone(133) 244-3000FaxN/AEmployees14,754Year Founded1923Profitability EPS (Most Recent Fiscal Year)$0.21 Trailing P/E Ratio48.05 Forward P/E Ratio16.27 P/E GrowthN/ANet Income$113 million Net Margins3.26% Pretax Margin1.55% Return on Equity10.33% Return on Assets4.62% Debt Debt-to-Equity Ratio0.26 Current Ratio0.90 Quick Ratio0.72 Sales & Book Value Annual Sales$11.11 billion Price / Sales1.64 Cash Flow$1.16 per share Price / Cash Flow8.72 Book Value$5.84 per share Price / Book1.73Miscellaneous Outstanding Shares1,809,663,000Free FloatN/AMarket Cap$18.26 billion OptionableNot Optionable Beta0.36 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:ALPMY) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.